Currency In USD
| Previous Close | 3.08 |
| Open | 3.1 |
| Day High | 3.1 |
| Day Low | 3.03 |
| 52-Week High | 16 |
| 52-Week Low | 2.66 |
| Volume | 279,367 |
| Average Volume | 1.73M |
| Market Cap | 57.96M |
| PE | -1.4 |
| EPS | -2.17 |
| Moving Average 50 Days | 3.78 |
| Moving Average 200 Days | 8.33 |
| Change | -0.04 |
Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 25, 2026 1:00 PM GMT
BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that R
Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial
GlobeNewswire Inc.
Dec 11, 2025 1:00 PM GMT
Antigen spreading was evaluated in a subset of Phase 2 patients to assess the ability of ELI-002 7P to broaden immune responses to personalized tumor neoantigens not present in the targeted immunotherapy87% (13/15) of evaluated patients demonstrated
Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer
GlobeNewswire Inc.
Nov 19, 2025 1:00 PM GMT
Strategic Hire Strengthens Late Phase and Commercial Readiness as Elicio Advances Lymph Node-Targeted Immunotherapy PipelineBOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-st